Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824986) titled 'A Phase 3 Trial in Advanced Epithelioid Mesothelioma' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Vivace Therapeutics, Inc
Condition:
Pleural Mesothelioma
Mesothelioma
Intervention:
Drug: VT3989
Drug: gemcitabine
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 1, 2026
Target Sample Size: 350
To know more, visit https://clinicaltrials.gov/study/NCT07824986
Disclaimer: Curated by HT Syndication....